BEL, Inc. is a deep-tech company specializing in materials science and surface engineering, focusing on the development and social implementation of advanced functional surfaces with antibacterial, antiviral, and anti-biofilm properties. The company integrates polymer science, additive manufacturing (3D printing), and surface microstructure control to create next-generation functional coatings for applications in medical devices, infrastructure, environmental systems, and marine environments. BEL actively promotes international collaboration with universities, research institutes, and industrial partners, aiming to advance materials innovation by integrating materials science with digital technologies such as data science and digital twin methodologies.
A drug discovery venture tackling next-generation cancer treatment using marine-derived compounds that improve tumor hypoxia while minimizing side effects. Already commercialized as veterinary medicine, it supports the lives of both humans and pets.
A startup developing kidney disease treatments and cell therapies using iPS cell technology, expanding its achievements in the kidney disease field while advancing applications to the liver and pancreas.
KDDD (Kyoto Drug Discovery and Development) is a spin-off company from Kyoto University. Our project is based on a result of research by Department of Ophthalmology Kyoto University and Graduate School of Biostudies. We sincerely aim to develop an innovative agent effective for various INCURABLE or INTRACTABLE eye diseases, especially CRAO, Retinal Pigmentosa, AMD and Glaucoma.
【Neoself Platform for Clinical Diagnostics and Drug Development】 AOI Bio leverages a newly discovered mechanism, coined Neoself, underlying autoimmune diseases to provide diagnostic services and to develop novel therapeutics. AOI Bio. currently offers clinical testing for the B2GPI Neoself Antibody in patients with unexplained recurrent pregnancy or implantation failures. 【Bioinformatics Analysis Platform for Drug Discovery】 AOI Bio employs advanced computational methods to identify novel biomarkers and drug candidates. By utilizing industry-leading solutions, such as quantum-optimized allosteric pocket identification, AOI Bio. drives its groundbreaking drug development efforts forward.
